Ephemeral to build AI data platform for Plus CNS oncology programs
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.
Plus Therapeutics has signed an agreement with Ephemeral Technologies to develop an AI execution platform for CNS oncology. The platform is intended to integrate therapeutic, diagnostic, and bioinformatics datasets across Plus’ CNS oncology programs.
Ephemeral was founded by former co-heads of Palantir Technologies’ U.S. healthcare business. Plus said the company will help assess and implement AI-enabled data infrastructure for complex CNS oncology datasets.
Longitudinal data from Plus’ therapeutic and diagnostic workflows will be organized and analyzed through the platform, according to the announcement. No financial terms were disclosed.
Beginning in 2026, Plus said it expects the partnership to support laboratory and clinical operating efficiency and workflows. Longer-term planned uses include operational decision support, translational analytics, treatment-response analytics, patient stratification, precision oncology, pharmaceutical collaborations, and real-world evidence initiatives.
Plus Therapeutics is a Houston-based clinical-stage company developing targeted radiotherapeutics for central nervous system cancers. Its lead programs include leptomeningeal metastases and recurrent glioblastoma.
CNSide Diagnostics, a wholly owned Plus subsidiary, develops laboratory-developed tests including CNSide, a cerebrospinal fluid assay platform for analyzing tumor cells that have metastasized to the central nervous system.
Company:Plus Therapeutics
Plus Therapeutics coverage
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Niowave Lansing site to scale Ac-225 supply by 2028
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.
30-year GE-UW tie expands into CT and theranostics research
The collaboration will focus on CT and molecular imaging technologies for cardiology, oncology, and theranostics workflows at UW Medicine Radiology facilities in Seattle.
Recall issues and isotope shortages weigh on Radnostix Q1 revenue
The radioisotope-focused company reported $2.38M in Q1 revenue, citing recall impacts, isotope shortages, and Cobalt-60 hot cell downtime.
Fujifilm balloon-free EBUS scope targets pulmonary setup time
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.
ACIST Pro brings contrast tracking upgrade to U.S. cath labs
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.
Braid Health launches $199 radiology second-opinion service
Patients can upload MRI, CT, X-ray, or ultrasound files and receive a written second opinion from a board-certified U.S. radiologist.
QT Imaging prices $10M raise for breast imaging platform
QT Imaging Holdings priced a $10M underwritten public offering of common stock and pre-funded warrants. The breast imaging technology company plans to use proceeds for working capital and general corporate purposes.
PSMA PET guidance anchors EDAP-Telix HIFU prostate work
EDAP TMS and Telix Pharmaceuticals signed a letter of intent to explore clinical research combining Focal One Robotic HIFU with Telix PSMA PET imaging agents in prostate cancer care.
UnitedHealthcare cites radiology costs in Maryland premium request
UnitedHealthcare is seeking an average 7.9% mid-year premium increase for some Maryland small-group plans. The insurer cited rising outpatient costs, including radiology, lab pathology, infusion, and radiation therapy.
Lumexa adds 4 imaging centers, including first UPMC JV site
Lumexa Imaging added 4 outpatient imaging centers across Pennsylvania, North Carolina, South Carolina, and Florida. The expansion includes acquired centers through joint ventures with UPMC and Advocate Health, plus 2 newly built locations.
PAI report finds 82% of U.S. physicians are now employed
A new PAI-Avalere report found that 82% of U.S. physicians are employed by hospitals, health systems, or corporate entities. Physician-owned settings now account for 18% of physicians and 36.1% of practices.
TerraPower breaks ground on Ac-225 isotope facility
TerraPower Isotopes has broken ground on a $450M actinium-225 manufacturing facility in Philadelphia. The company said the site will increase global Ac-225 production capacity 20-fold.